Roche granted breakthrough status for live...Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giant’s mAb combination therapy for liver cancer. more ➔
Epigenetic biomarkers predict immunotherap...UK biotech Oxford BioDynamics has presented data showing that the company’s blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. more ➔
Urovant launches US$150m IPOSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron. more ➔
Immunooncology: Genmab teams up with Immat...Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications. more ➔
Big Data: Tracking cancer risk genesUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk. more ➔
Lifecare floats on Oslo stock exchangeNorwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor. more ➔
Abingworth closes new biotech fund at €2...Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US. more ➔
€47m for rare disease biotechAfter €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for … more ➔
€7m for French microbiome start-upMicrobiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases. more ➔
Highs and lows for Fresenius Medical CareDialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price. more ➔
